T 20 / Triastek - LARVOL DELTA

Triastek’s 3D-Printed Gastric Retention Product T20G Receives FDA IND Clearance (Businesswire) - "Today, Triastek announces that on February 27, 2025 a proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This regulatory milestone follows the prior IND clearance of this product by China's National Medical Products Administration (NMPA) in January 2024...T20G is being developed by using a novel dosage form (or drug delivery system) under the FDA's 505(b)(2) New Drug Application (NDA) pathway. Triastek holds exclusive global intellectual and commercialization rights for this innovative therapeutic candidate."

IND • Atrial Fibrillation